ArticleBMC infectious diseases2026
Antimicrobial resistance and documented empirical antibiotic prescribing among cancer patients with culture-confirmed infections at a tertiary referral hospital in Rwanda, 2019-2024.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance (AMR) threatens infection management in cancer patients, yet data from sub-Saharan African oncology settings are scarce. We described the microbiology, resistance patterns and documented empirical prescribing among cancer patients with culture-confirmed infection in Rwanda.
methodsWe conducted a retrospective, records-based study of 297 culture-confirmed infection episodes in 286 cancer patients at King Faisal Hospital, Kigali, from 2019 to 2024. Routine susceptibility results were interpreted with the Clinical and Laboratory Standards Institute breakpoints in use at the time. Multidrug resistance (MDR) was classified with the organism-specific definitions of Magiorakos et al., which covered 232 of 254 bacterial isolates. Factors associated with MDR were examined by modified Poisson regression (adjusted prevalence ratios, aPR) with sensitivity analyses. Empirical regimens documented in the electronic medical record (EMR; 105 episodes, 100 inpatient) were compared with the WHO AWaRe framework and the 2022 Rwanda Standard Treatment Guidelines.
resultsUrinary tract infections (UTIs) predominated (172/297; 57.9%). Escherichia coli (101/297; 34.0%), Klebsiella spp. (32/297; 10.8%) and Enterococcus spp. (25/297; 8.4%) were the commonest isolates, and ESKAPEE pathogens accounted for 201/297 episodes (67.7%). MDR was identified in 138 of 232 covered isolates (59.5%; 95% CI 53.1-65.6) and 138 of 214 classifiable isolates (64.5%; 95% CI 57.9-70.6); restricting to more complete panels increased the estimate. Ceftriaxone resistance was high (E. coli 65/87, 74.7%; Klebsiella spp. 20/29, 69.0%), and carbapenem resistance in Acinetobacter spp. was 8/13 (61.5%). MDR prevalence did not differ by infection type (aPR versus UTI: bloodstream 0.94, 95% CI 0.67-1.31; skin and soft tissue 0.98, 95% CI 0.72-1.34) and was lower among gram-positive isolates (aPR 0.42, 95% CI 0.21-0.85), owing to Enterococcus spp. Adherence of documented regimens to the national guideline was lowest for UTIs (1/43; 2.3%). Outpatient empirical prescribing was rarely documented in the EMR and could not be evaluated.
conclusionsMDR was common across all infection types, and ceftriaxone, the most frequently documented empirical agent, showed limited in vitro activity against the prevailing isolates. Whether oncology-specific empirical protocols based on local antibiograms are warranted should be evaluated prospectively, including clinical outcomes, alongside AWaRe-aligned stewardship and better documentation of prescribing.
Indexed as
Identifiers
42919245What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.